Updated:
Paragon Biosciences
Paragon Biosciences, founded by Jeff Aronin in 2017, builds biotech companies around targeted neuroscience and rare-disease assets from its Chicago base.
Paragon Biosciences
Founded by serial life sciences entrepreneur Jeff Aronin in 2017, Paragon Biosciences operates from Chicago with a highly structured approach to company creation. Aronin previously founded and led Ovation Pharmaceuticals, which he sold to Lundbeck in 2009 for $900 million, and Marathon Pharmaceuticals. This operator-first background shapes Paragon's identity: the firm does not passively invest in early-stage biotech but instead builds companies around specific, scientifically validated assets. Paragon's investment strategy centers on forming portfolio companies that address serious unmet medical needs, primarily in rare diseases and neuroscience. The firm concentrates on biotechnology, digital health, and AI-enabled drug discovery. Its incubation model provides capital, operational infrastructure, and regulatory expertise to accelerate assets through clinical development. Confirmed portfolio companies include Harmony Biosciences (NASDAQ: HRMY), which Paragon founded and took public in 2020, Castle Creek Biosciences, and Evozyne, an AI-driven protein engineering company (per the firm's official communications). At least one portfolio venture also focused on synthetic biology and industrial biotechnology. The firm's team includes professionals with deep pharmaceutical and regulatory experience, though an exact headcount is not publicly disclosed. Paragon's capital deployment includes commitments to single-asset biotech platforms, and it has historically used a combination of venture rounds and public-market exits. In October 2023, Paragon portfolio company Harmony Biosciences acquired Zynerba Pharmaceuticals in a transaction valued at approximately $200 million (per Harmony Biosciences, October 2023). The firm's operational model means that portfolio companies often share centralized support functions like clinical operations and regulatory affairs housed at the Chicago headquarters. Paragon's structural differentiator is its centralized therapeutic-area focus combined with an incubation-and-exit repeatability model. Unlike a generalist venture firm that places bets across stages and sectors, Paragon builds companies one at a time within a narrow neuroscience and rare-disease thesis, then takes them public. This creates a procedural replication advantage: the same regulatory playbook, the same key opinion leader networks, and the same commercialization pathways are reused across portfolio companies. The close tie between Paragon and the management teams of its incubated companies, with Aronin often serving as chairman, embeds founder-level oversight into each entity.
General information
Firm type
Asset Manager
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chicago
Corporate office
Chicago, IL, United States
Principals
Jeff Aronin
Founder, Chairman & CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Paragon Biosciences?
Founder, Chairman and CEO Jeff Aronin directs all major capital-allocation and portfolio-formation decisions. Aronin's prior track record includes building and selling Ovation Pharmaceuticals to Lundbeck for $900 million (public record). His operating experience means investment decisions are filtered through a developer's lens — the firm only advances assets where the regulatory and clinical pathway is well-defined.
How is Paragon Biosciences typically capitalized?
Paragon does not publicly disclose its total assets under management or fund structure. The firm has historically invested its own capital alongside external co-investors in portfolio companies, with Harmony Biosciences raising both private venture rounds before listing on Nasdaq in 2020 (per public filings, 2020). The absence of publicly reported fund close announcements suggests a flexible, deal-by-deal capital formation model rather than a traditional blind-pool venture fund.
What distinguishes Paragon's company-building model from a standard venture approach?
Paragon operates as an incubator and company builder, not a passive minority investor. The firm identifies specific underserved disease targets, forms a legal entity around that asset, and staffs the management team with operators who have deep domain expertise — often drawing from Aronin's industry network. Harmony Biosciences, its most visible success, was built entirely within Paragon's infrastructure before its public listing.
What therapeutic areas does Paragon Biosciences focus on?
The firm concentrates on neuroscience, rare diseases, and related digital-health applications. Within neuroscience, its primary focus has been sleep disorders and other central nervous system conditions, as demonstrated by Harmony Biosciences' flagship product for narcolepsy. Paragon has also signaled interest in AI-enabled drug discovery through portfolio company Evozyne.
Does Paragon Biosciences invest outside of therapeutics?
While the firm's core activity is in biotechnology and pharmaceuticals, it has expanded into adjacent fields like AI-driven protein engineering and synthetic biology through companies including Evozyne. Digital health applications that support clinical development or patient monitoring are also within scope. The firm does not invest in medical devices, diagnostics, or healthcare services as standalone sectors.
How is Paragon Biosciences related to Harmony Biosciences?
Paragon founded Harmony Biosciences and took it public on Nasdaq in 2020. Jeff Aronin served as Chairman of Harmony's board, and the two firms share a deep operational history. Harmony operates as an independent public company with its own management team, but its founding inside Paragon's incubation model means the firms have historically shared certain personnel and advisors.
What is Paragon's known posture on co-investments?
Paragon's public disclosures and portfolio-company capitalization records indicate openness to syndicating alongside external investors. Harmony Biosciences raised capital from venture investors prior to its IPO, and the firm's other incubated companies have brought in co-investors for specific funding rounds. Paragon appears to retain significant ownership positions rather than syndicating out control.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: